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WHAT THIS PAPER ADDS
 A systematic review and meta-analysis of randomised controlled trials was conducted, which aim to compare clinical outcomes
between concurrent minimally invasive procedures and surgery for treating varicose veins. All relevant randomised controlled
trials published up to August 2011were included. Treatment comparisonswere endovenous laser ablation, radiofrequency ablation,
ultrasound-guided foam sclerotherapy and surgery. Clinical relevant outcomes, that is, primary failure, clinical recurrence, post-
operative complications, pain and return to normal activities were covered. Evidence and recommendation suggested from our
study were provided.a r t i c l e i n f o
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Objectives and design: A systematic review and meta-analysis was conducted to compare clinical
outcomes between endovenous laser ablation (EVLA), radiofrequency ablation (RFA), ultrasound-guided
foam sclerotherapy (UGFS) and surgery.
Methods:We searched MEDLINE and Scopus from 2000 to August 2011 to identify randomised controlled
trials (RCTs) comparing EVLA, RFA, UGFS, and surgery or combinations of these for treatment of varicoses.
Differences in clinical outcomes were expressed as pooled risk ratio and unstandardised mean difference
for dichotomous and continuous outcomes, respectively. Methodological quality was assessed using
Cochrane tools.
Results: Twenty-eight RCTs were included. The primary failure and clinical recurrences were not
signiﬁcantly different between EVLA and RFA versus surgery with the pooled RR of 1.5 (95%CI:0.7, 3.0)
and 1.3 (95%CI:0.7, 2.4) respectively for primary failure, and, 0.6 (95%CI:0.3, 1.1) and 0.9 (95%CI:0.6, 1.4)
respectively for clinical recurrences. The endovenous techniques had advantages over surgery in
lowering wound infections (RR ¼ 0.3 (95%CI:0.1, 0.8) for EVLA), haematoma (RR ¼ 0.5 (95%CI:0.3, 0.8) and
0.4 (95%CI:0.1, 0.8) for EVLA and RFA), and return to normal activities or work (mean differences ¼ 4.9
days (95%CI:7.1,2.7) for RFA).
Conclusions: The primary failure and recurrence in EVLA and RFA were non-signiﬁcantly different
compared with surgery. However, they had lower haematoma, less wound infection, less pain and
quicker return to normal activities.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.tions on this paper, please go
662 2011284.
ian).
ciety for Vascular Surgery. PublishMinimally invasive endovenous procedures (MIEPs) have been
recently introduced for treating varicose veins to reduce post-
operative complications, speed recovery and improve quality of life
(QOL) compared to standard surgery.1e3 These methods have beened by Elsevier Ltd. All rights reserved.
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rotherapy (UGFS), radiofrequency ablation (RFA), and endovenous
laser ablation (EVLA)), with less surgery and doubling of endove-
nous procedures during 2007e2008 in the UK.4
Although previous systematic reviews1e3,5,6 favoured MIEPs,
that is, similar efﬁcacies but less complications, and shorter time to
work, these results may bias since pooling effects were mainly
based on observation studies or mixed with randomised controlled
trials (RCTs). Some RCTs have been later published.7e17 We there-
fore conducted a systematic review and meta-analysis solely of
RCTs comparing all relevant outcomes including efﬁcacies (i.e.,
primary failure and clinical recurrence), postoperative complica-
tions (i.e., wound infection, paresthesia, superﬁcial thrombophle-
bitis, haematoma and ecchymosis), postoperative pain, time return
to normal activities or work and QOL between these MIEPs and
surgery and between MIEPs themselves.
Methods
Search strategy
We searched in MEDLINE and Scopus from 2000 to 20 August
2011. Search terms were (‘varicose veins’[Mesh], ‘saphenous
vein’[Mesh], varicose and saphenous), (radiofrequency, RFA, VNUS,
‘endovenous laser’, EVLT, EVLA, sclerotherapy[Mesh], ‘foam scle-
rotherapy’, microfoam, stripping and sapheno-femoral ligation)
and (obliteration, occlusion, recurrence, recurrent, recanalisation,
neovascularisation, reﬂux, pain, ‘return to normal activities’, ‘return
to work’, haematoma, paresthesia, ‘nerve injury’, ‘wound infection’,
deep vein thrombosis (DVT) and thromboembolism). Reference
lists of previous meta-analyses and all eligible papers were also
explored.
Study selection
Identiﬁed studies were selected by two independent authors
(B.S. and P.N.). Disagreements in selection were reviewed and
adjudicated by a third party (A.T). For multiple publications, the
relevant data were combined as one publication for analysis.
The inclusion criteria for eligible studies were as follows: RCTs,
compared outcomes between any of MIEPs and surgery or between
MIEPs in patients with great saphenous vein reﬂux, reported at
least one outcome of interest. Studies were excluded if they were
not English or had insufﬁcient data.
Data extraction
B.S. and P.N. extracted data using a standardised extraction form.
Disagreements were resolved by consensus and checked by A.T.
Corresponding authors were contacted twice for missing infor-
mation. The mean and SD were estimated from median and range
for analysis.18
Risk of bias assessment
This was done by the same authors (B.S. and P.N.) using the
Cochrane tool.19 These considered six domains as follows: was
allocation sequence adequately generated?, was allocation
adequately concealed?, was knowledge of the allocated interven-
tions adequately blinded?, were incomplete outcomes adequately
addressed?, were reports free from selection?, and was there other
source of bias (e.g., imbalance of patient characteristic between
groups, protocol violation and the method dealing with data
(intention to treat or per-protocol analysis))? Disagreements were
resolved by A.T.Outcomes
The primary outcomewas failure to completely abolish reﬂux in
the axial vein. SinceMIEPs and surgery use different mechanisms to
abolish reﬂuxes, each had different failure deﬁnitions. Primary
failure was recanalisation diagnosed by duplex scan for MIEPs:
incomplete stripping, incomplete removal of an intended vein or
recanalisation for surgery. Numbers of primary failure at the end of
study were used for analysis. Failure to cannulate or pass a guide
wire was considered as technical failure, and not analysed.
Secondary outcomes were clinical recurrences assessed by
physical examination (e.g., visible or palpable varicose), venous
clinical severity scores (VCSSs), postoperative complications (i.e.,
wound infection, paresthesia, superﬁcial thrombophlebitis, hae-
matoma or ecchymosis), postoperative pain, time return to normal
activities or work and QOL measured by Aberdeen varicose vein
severity score (AVVSS). The secondary outcomes were measured at
the end of study except complications and pain. Since complica-
tions were reported at different follow-up times, the maximum
numbers were analysed. If a study reported both time return to
normal activities and time to work, the former was used. First
recorded and highest pain scores by visual analogue scale (VAS)
were used to pool. Only thigh haematomas were pooled.
Statistical analysis
Data were pooled if there were at least three studies for each
comparison. Risk ratios (RRs) and 95% conﬁdence intervals (CIs)
were estimated and pooled. If there was a zero cell, a continuity
correction was used. The RRs were pooled using the DerSimonian
and Laird if heterogeneity was present, otherwise the inverse
variance was applied. For continuous data, mean differences (MDs)
along were estimated and pooled using an unstandardised method.
Q test and the degree of heterogeneity (I2) were used to assess
heterogeneity. If either I2  25% or the Q test was signiﬁcant, the
random-effect model was used. Heterogeneity source was explored
by ﬁtting covariables (i.e., mean age, follow-up time and wave-
length) in a meta-regression. If the co-variable could reduce the I2,
a subgroup or sensitivity analysis of that factor was performed.
Publication bias was assessed by Egger test and funnel plot.20
The possible cause of asymmetry (e.g., heterogeneity or reporting
bias) was explored using a contour-enhanced funnel.20,21 Themeta-
trim and ﬁll was applied to impute missing studies. Analyses were
performed using STATA version 12.0. A p-value <0.05 was consid-
ered statistically signiﬁcant, except for the heterogeneity test,
where a 0.10 was used.
Results
Seventy-seven and 66 RCTs from MEDLINE and Scopus were
identiﬁed (see Fig. 1). After removing duplicates, 91 studies were
screened out, leaving 28 studies for data extraction. Among them,
11 RCTs7e10,22e28 compared EVLA with surgery, 8 RCTs11,12,29e34
compared RFA with surgery, 4 RCTs13,14,35,36 compared UGFS with
surgery and 5 RCTs15e17,37,38 compared RFA with EVLA with one
multiple comparison study.38
General characteristics of the eligible studies are presented in
Table 1. Sample sizes ranged from 16 to 500 patients involving
28e580 limbs. The mean age ranged from 33 to 55 years, and
duration of follow-up was 1 weeke5 years. Most included patients
were within CEAP C2 category. The risk of bias assessment is pre-
sented, the highest quality was other source of bias from applying
intention to treat analysis (83%), follows with allocation conceal-
ment and selective outcome report (78%) whereas the lowest was
blinding (43%) (see Table 2).
Figure 1. Studies selection ﬂow.
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EVLA versus surgery
Nine studies8e10,22e24,26,28,38 compared primary failure between
EVLA and surgery with 712 and 675 limbs, respectively. The
heterogeneity was moderate (Q ¼ 11.60, d.f. ¼ 8, p ¼ 0.170,
I2 ¼ 31.1%) with the pooled RR of 1.5 (95%CI:0.7, 3.0) (see Fig. 2A),
suggesting that EVLA had 1.5 times higher risk of primary failure
than surgery but this was non-signiﬁcant.
Fitting age, follow-up time, pull-back type and wavelength in the
meta-regression suggest that only wavelength might be a source of
heterogeneity. Pooling studies using wavelengths of 8102326,28 and
980 nm8e10,38 yielded homogenous results (I2 ¼ 26.5% and 0%,
respectively) with the pooled RR of 0.95 (95% CI:0.39, 2.32) and 2.36
(95% CI:0.96, 5.76), respectively. A subgroup analysis within studies
<1- and 1-year follow-up resulted in the pooled RR of 3.5 (95%
CI:0.7, 17.1) and 1.3 (95% CI:0.5, 3.0), respectively. A sensitivity
analysis excluding three studies with different techniques (cry-
ostripping25 and EVLAwith high ligation24,28) yielded the pooled RR
of 1.3 (95% CI:0.5, 3.0) with I2 of 44.6%.
RFA versus surgery
Seven studies11,12,29e32,38 compared primary failure between
RFA and surgery (n ¼ 381 vs 378 limbs) with low heterogeneity
(Q ¼ 7.46, d.f. ¼ 6, p ¼ 0.281, I2 ¼ 19.5%) with a pooled RR of 1.3
(95% CI:0.7, 2.4) (see Fig. 2B). ClosureVNUS was applied to all
except one study38 which used ClosureFAST catheter. Excluding
this study did not change much results (pooled RR ¼ 1.19, 95%
CI:0.57, 2.47).
A sensitivity analysis by excluding the cryostripping study29
yielded the pooled RR of 1.2 (95% CI:0.5, 2.8). The pooled RRs
were 0.9 (95% CI:0.3, 2.8) and 2.0 (95% CI:0.8, 5.1) for studies with
<1- and 1-year follow-up.UGFS versus surgery
Five studies13,14,35,36,38 compared primary failure between UGFS
and surgery with 406 and 350 limbs, respectively. The pooled RR
was 2.4 (95%CI:1.6, 3.6) with low heterogeneity (Q ¼ 5.17, d.f. ¼ 4,
p ¼ 0.270, I2 ¼ 22.7%) (see Fig. 2C), suggesting that UGFS was about
twofold higher risk of failure. Subgroup analysis by follow-up time
<1 and 1 year yielded the pooled RRs of 1.3 (95% CI:0.6, 2.9) and
3.1 (95% CI:1.8, 5.3), respectively.
RFA versus EVLA
Four studies15,17,37,38 compared primary failure between RFA and
EVLA (n ¼ 304 vs 296 limbs) with moderate heterogeneity
(Q ¼ 4.39, d.f. ¼ 3, p ¼ 0.222, I2 ¼ 31.7%) with the pooled RR of 1.5
(95% CI:0.7, 3.4) (see Fig. 2D). Pooling studies with17,38 and
without15,37 applying ClosureFast yielded the pooled RR of 0.84
(95% CI:0.30, 2.34) and 2.36 (95% CI:0.55, 10.15), respectively.
Publication bias was assessed and suggested that there was no
evidence of publication bias for all comparisons of primary failure
except for EVLA versus surgery (see Fig. 3AeD), in which the Egger
test and the contour-enhanced funnel plot suggested asymmetry
(see Fig. 3A). All except one study fell in the non-signiﬁcant area,
suggesting that the cause of asymmetry may be heterogeneity
rather than publication bias. Meta-trim and ﬁll indicated four
missing studies, and pooling these with existing nine studies
resulted in pooled RR of 1.0 (95% CI:0.4, 2.1).
Clinical recurrence
EVLA versus surgery
Four studies8,10,23,38 comparing clinical recurrences between
EVLA and surgery were pooled (n ¼ 395 and 397 limbs) with
moderate heterogeneity (Q ¼ 6.63, d.f. ¼ 3, p ¼ 0.085, I2 ¼ 54.8%)
(see Fig. 4A). The pooled RR was 0.6 (95% CI:0.3, 1.1), indicating
Table 1
General characteristics of eligible studies.
Source
(year of publication)
Duration of
follow-up
Intervention No. of limbs Mean age Severity Anaesthesia Compression technique TA CP
EVLA vs surgery
Demeideros28 (2005) 13 days EVLA 810 nm plus
high ligation
Conventional
20
20
46
46
C2-3(55%),
C4-6(45%)
C2-3(80%),
C4-620%)
RA
RA
Compression wrap 2 days
Compression wrap 2 days
No
No
Yes
Yes
Darwood26 (2008) 12 months EVLA 810 nm(step.)
EVLA 810 nm(cont.)
Inversion
47
29
32
40
46
44
C2-3(87%),
C4-5(11%)
C2-3(91%),
C4-5(3%)
C2-3(94%),
C4-5(3%)
LA
LA
GA
CS 1 week
CS 1 week
CS 2 weeks
Yes
Yes
No
No
No
Yes
Disselhoff25 (2008) 60 months EVLA 810 nm
Cryostripping
60
60
49
49
C2(100%)
C2(100%)
GA, LA
GA, LA
CS 1 week
CS 1 week
Yes(LA),
TS(GA)
e
No
No
Kalteis24 (2008) 4 months EVLA 810 nm plus
high ligation
Conventional
47
48
42
42
C2-3(93%),
C4(7%)
C2-3(96%),
C4(4%)
GA, RA
GA, RA
CS 2 weeks
CS 2 weeks
No
No
Yes
Yes
Christenson9 (2010) 24 months EVLA 980 nm
Conventional
100
100
45
46
C2-3(92%),
C4-6(8%)
C2-3(77%),
C4-6(23%)
GA, RA
GA, RA
CS 3 weeks
CS 3 weeks
Yes
No
Yes
Yes
Pronk8 (2010) 12 months EVLA 980 nm
Inversion
62
68
49
50
C2-3(94%),
C4-5(6%)
C2-3(91%),
C4-5(8%)
LA
LA
Panelast 1 week
Panelast 1 week
Yes
Yes
No
No
Rasmussen10,27
(2007, 2010)
24 months EVLA 980 nm
Invagination
69
68
53
54
C2-3(85%),
C4(15%)
C2-3(94%),
C4(5%)
LA
LA
CS 2 weeks
CS 2 weeks
Yes
Yes
Yes
Yes
Carradice7 (2011) 12 months EVLA 810 nm
Inversion
139
137
49
49
C2(69%),
C3(31%)
C2(70%),
C3(30%)
LA
GA
CS 6 weeks
CS 6 weeks
Yes
No
Yes
Yes
RFA vs surgery
Lurie32,33 (2003, 2005) 24 months RFA (Closure)
Invagination
45
36
49
47
C2-3(90%),
C4(9%)
C2-3(89%),
C4(11%)
GA,RA,LA
GA,RA,LA
e
e
TA(some)
TA(some)
Yes
Yes
Rautio,34 Perala31
(2002, 2005)
36 months RFA (Closure)
Conventional
15
13
33
38
e GA
GA
CS 7 days
CS 7 days
TS
No
Yes
Yes
Hinchliffe30 (2006) 6 weeks RFA (VNUS)
Inversion
16
16
55
55
C2-3(94%),
C4(6%)
C2-3(94%),
C4(6%)
GA, RA
GA, RA
CS 2 weeks
CS 2 weeks
TS
No
Yes
Yes
Stoetter29 (2006) 12 months RFA (Closure)
Invagination
Cryostripping
20
20
20
e e GA
e
e
CS 6 weeks
CS 6 weeks
CS 6 weeks
TS
e
e
e
e
e
Subramonia12 (2010) 1 week RFA (ClosurePLUS)
Invagination
47
41
44
41
C2-3(98%),
C4(2%)
C2-3(98%),
C6(2%)
GA
GA
CS 2 weeks
CS 2 weeks
Yes
e
Yes
Yes
Elkaffas11 (2011) 23 months RFA (Closure)
Conventional
90
90
33
35
C2-3(87%),
C4-5(13%)
C2-3(87%),
C4-5(13%)
LA
GA
e
e
Yes
e
Yes
Yes
UGFS vs surgery
Bountouroglou36 (2006) 3 months UGFS
Inversion
30
28
45
46
e LA
GA
CS 2 weeks
CS 3 weeks
e
e
No
Yes
Wright35 (2006) 12 months Varisolve
High ligation(92%),
stripping(88%),
avulsion phlebectomy(53%)
178
94
50
49
C2-3(89%),
C4(11%)
C2-3(89%),
C4(11%)
LA
GA,RA,LA
CS
e
e
e
No
Yes
Abela14 (2008) 2 weeks Catheter directed UGFS
Conventional, Invagiantion
30
60
45
45
C2-3 (100%)
C2-3 (100%)
GA
GA
CS 15 days
CS 15 days
Yes
Yes
Yes
Yes
Figueiredo13 (2009) 6 months UGFS,repeat up to
3 times q 30 days
Conventional
27
29
53
49
e LA
RA
CS 3 months
CS 3 months
No
Not
stated
No
Yes
RFA vs EVLA
Almeida17 (2009) 1 month RFA (ClosureFAST)
EVLA 980 nm
46
41
52
52
C2 (94%)
C2 (88%)
LA
LA
CS 2 weeks
CS 2 weeks
Yes
Yes
No
No
Gale15 (2010) 12 months RFA (ClosurePLUS)
EVLA 810 nm
70
72
49
51
e LA
LA
CS 2 weeks
CS 2 weeks
Yes
Yes
Yes
Yes
(continued on next page)
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Table 1 (continued )
Source
(year of publication)
Duration of
follow-up
Intervention No. of limbs Mean age Severity Anaesthesia Compression technique TA CP
Goode37 (2010) 9 months RFA (RFiTT)
EVLA 810 nm
40
39
46
48
e GA
GA
CS 2 weeks
CS 2 weeks
TS(some)
TS
Yes
Yes
Shepherd16 (2010) 6 weeks RFA (ClosureFAST)
EVLA 980 nm
66
61
49
48
C2 (35%),
C3-6 (65%)
C2 (41%),
C3-6 (58%)
GA
GA
CS 1 week
CS 1 week
Yes
Yes
Yes
Yes
Multiple comparisons
Rasmussen38 (2011) 12 months EVLA 980, 1470 nm 125 52 C2-3 (95%),
C4-6 (5%)
LA Short CS 20 mmHg 2 weeks Yes Yes
RFA (ClosureFAST) 125 51 C2-3 (92%),
C4-6 (8%)
LA Short CS 20 mmHg 2 weeks Yes Yes
UGFS, retreatment
allowed in 1 month
124 51 C2-3 (96%),
C4-6 (4%)
LA Groin 30 mmHg CS 2 weeks No Yes
Pin stripping 124 50 C2-3 (97%),
C4-6 (3%)
LA Short CS 20 mmHg 2 weeks Yes Yes
Step., stepwise mode; cont., continuous mode; TA, Tumescent anaesthesia; TS, Tumescent saline; LA, Local anaesthesia; GA, General anaesthesia; RA, Regional anaesthesia; CP,
Concomitant phlebectomy; CS, compression stocking.
B. Siribumrungwong et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 214e223218that EVLA had 40% less chance of clinical recurrence, but this
was non-statistically signiﬁcant. Source of heterogeneity (i.e.,
age and follow-up time) could not be identiﬁed. A sensitivity
analysis was performed by excluding one study8 that did not
undertake concomitant phlebectomies yielded very similar
results.
RFA versus surgery
The RRs of clinical recurrence between RFA versus surgery were
homogeneous (Q ¼ 2.97, d.f. ¼ 3, p ¼ 0.396, I2 ¼ 0%) among four
studies11,31e33,38 with a pooled RR of 0.9 (95% CI:0.6, 1.4) (see Fig. 4B).
Venous clinical severity score
Five studies9,23,25e27 compared VCSS between EVLA and surgery
with no heterogeneity (Supplementary Fig. 1). The pooled MD
was 0.01 (95% CI:0.07, 0.06).
Table 2
Risk of bias assessment of eligible studies.
Author Domains
Sequence Generation Allocation concealment Blinding Incompl
EVLA vs surgery
Carradice7 Unclear Yes Yes Yes
Rasmussen10,27 Unclear Yes No Yes
Pronk8 Yes Yes No Yes
Christenson9 Yes Yes No No
Kalteis24 No No No Yes
Disselhoff22,25 Unclear Yes Yes Yes
Darwood26 Unclear Yes Yes No
Demedeiros28 Yes Yes Yes Yes
RFA vs surgery
Elkaffas11 Unclear Yes Yes Yes
Subramonia12 Yes Yes Yes Yes
Stoetter29 Unclear Unclear No Yes
Hinchliffe30 Unclear Unclear Yes Yes
Perala31,34 Unclear Yes No No
Lurie32,33 Unclear Yes No No
USFS vs surgery
Figueiredo13 Unclear Yes No Yes
Abela14 Yes Yes No Yes
Wright35 Unclear Yes No Yes
Bountouroglou36 Unclear Yes No No
RFA vs EVLA
Shepherd16 Unclear Yes Yes Yes
Goode37 Yes Unclear Yes No
Gale15 Unclear No No No
Almeida17 Yes Yes Yes Yes
Multiple comparisons
Rasmussen38 Unclear Yes No Yes
Yes ¼ Low risk of bias No ¼ High risk of bias Unclear ¼ uncertain risk of bias ITT, intentPostoperative complications
Wound infection
Eight7e9,24e27,38 and ﬁve studies11,12,30,33,38 reported wound
infections between EVLA and RFA versus surgery, respectively. The
corresponding pooled RRs were 0.3 (95% CI:0.1, 0.8) and 0.3 (95%
CI:0.1,1.4), with no heterogeneity (Table 3). Comparing overall EVLA
and RFAwith surgery based on 12 studies yielded a pooled RR of 0.3
(95%CI:0.1, 0.7) (Supplementary Fig. 2), that is, wound infectionwas
signiﬁcantly reduced by 70% in the endovenous techniques
compared with surgery. The estimated number needed to treat
(NNT) was 80 subjects to prevent one wound infection.
Paresthesia
Nine studies7e9,24e28,38 reported paresthesia between EVLA and
surgery. The RRs were homogeneous with the pooled RR of 0.8 (95%
CI:0.6, 1.1), suggesting no difference of paresthesia between groupsOther sources of bias Comments
ete outcome data Selective outcome report
Yes Yes Applied ITT
Yes Yes Applied ITT
No Yes Applied ITT
Yes No Applied PP
No No Applied PP
Yes Yes Applied ITT
Yes Yes Applied ITT
Yes Yes Applied ITT
Yes Yes Applied ITT
Yes Yes Applied ITT
No Yes Applied ITT
Yes Yes Applied ITT
Yes Yes Applied ITT
Yes Yes Applied ITT
Yes Yes Applied ITT
Yes Yes Applied ITT
Yes Yes Applied ITT
Yes Yes Applied ITT
Yes No Applied PP
No No Applied PP
No Yes Applied ITT
Yes Yes Applied ITT
Yes Yes Applied ITT
ion to treat analysis; PPA, per protocol analysis.
Figure 2. Forest plots of intervention effects on primary failure. The size of each square is proportional to percent weight that each study contributed in the pooled risk ratio. The
pooled risk ratio is indicated by the diamond . CI, conﬁdence interval ; RR , risk ratio.
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between RFA and surgery were moderately heterogeneous across
seven studies11,12,29,30,33,34,38 (see Table 3 and Supplementary
Fig. 3B). The pooled RR was 1.0 (95% CI:0.5, 1.7).
Superﬁcial thrombophlebitis
Six studies7,9,25e27,38 reported superﬁcial thrombophlebitis
between EVLA and surgery with homogeneity (see Table 3 and
Supplementary Fig. 4A). The pooled RRwas 1.0 (95% CI:0.5, 1.8). The
Egger test suggested asymmetry of funnel, adding one missing
study by meta-trim and ﬁll in the pooling yielded an RR of 0.9 (95%
CI:0.4, 1.8). To minimise confounding effects from tumescence
anaesthesia (TA), subgroup analysis according to similarity of
applying TA was performed. Two studies27,38 applied TA to both
groups, whereas four studies9,23,25,26 applied TA to only EVLA
group. This subgroup analysis yielded the pooled RRs of 1.0 (95%
CI:0.5, 2.2) and 0.8 (95% CI:0.3, 2.5), respectively.
Superﬁcial thrombophlebitis between RFA and surgery was
pooled from six studies11,12,30,33,34,38 with low heterogeneity. The
risk of superﬁcial thrombophlebitis was 2.3 (95% CI:1.1, 5.0) times
signiﬁcantly higher in RFA than surgery (see Table 3 and
Supplementary Fig. 4B). None of studies had similarity in applying
TA in both intervention groups.
Haematoma
Effects of EVLA versus surgery on haematoma were pooled in
four homogeneous studies7,9,24,27 (see Table 3). The pooled RR was0.5 (95% CI:0.3, 0.8), that is, EVLA had 50% signiﬁcant relative risk
reduction of haematoma (see Supplementary Fig. 5A). The esti-
mated NNT was 10. Among four studies, one study27 applied TA in
both EVLA and surgery, whereas another study24 did not apply in
both groups. Pooling these two studies yielded the pooled RR of 0.6
(95% CI:0.4, 0.9).
Effects of RFA versus surgery were highly heterogeneous across
ﬁve studies11,12,29,33,34 with the pooled RR of 0.4 (95% CI:0.1, 0.8),
suggesting that the risk of haematoma was 60% signiﬁcantly
reduced in RFA relative to surgery. The estimated NNT was four.
None of the studies were similar in applying TA.
Ecchymosis
Ecchymosis between EVLA and surgery was highly heteroge-
neous across six studies7,9,25e28 with the pooled RR of 0.7 (95%
CI:0.3,1.6) (see Table 3, and Supplementary Fig. 6). Pooling 2 studies
with similarity of applying TA (i.e., used27 and unused28 in both
groups) yield the pooled RR of 0.4 (95% CI:0.2, 0.7).Postoperative pain
As described in Table 4 and Supplementary Fig. 7, the ﬁrst-
recorded pain was signiﬁcantly lower after EVLA and RFA than
surgery with pooled MD of 0.6 (95% CI:1.1, 0.2) and 1.6 (95%
CI:2.1, 1.1), respectively. The RFA caused signiﬁcantly less pain
than EVLA with pooled MD of 0.8 (95% CI:1.5, 0.1).
Figure 4. Forest plots of intervention effects on clinical recurrence. CI, conﬁdence
interval ; RR , risk ratio.
Figure 3. Contour enhanced funnel plots of primary failure between various types of interventions.
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RFA than surgery with pooled MD of 0.6 (95% CI:1.0, 0.1)
and 1.6 (95% CI:2.0, 1.1), respectively. The maximum pain after
RFA was less than EVLA with an MD of 1.2 (95% CI:1.6,0.9).
Return to normal activities or work
Return to normal activities or work was signiﬁcantly shorter for
RFA but not for EVLA compared with surgery with pooled MD
of 4.9 days (95% CI:7.1, 2.7) and 2.7 (95% CI:6.0, 0.6) days,
respectively (see Table 4, Supplementary Fig. 8).
QOL
Six studies7,9,10,25,26,38 compared QOLmeasured at 2e24months
between EVLA versus surgery (see Table 4 and Supplementary
Fig. 9). The pooled MD was 0.2 (95%CI:0.9, 0.6) with heteroge-
neity. Fitting mean age, disease severity (percent C2-3) and follow-
up time in meta-regression did not suggest any source of hetero-
geneity (data were not shown).
Discussion
Our results suggest primary failure and recurrence rates after
EVLA and RFA were not signiﬁcantly different to surgery. However,
EVLA and RFA had 70% lower rates of wound infection, with NNT of
80. Also, both EVLA and RFA reduced haematoma by approximately
50e60%, with NNT of 4e10. Furthermore, patients could return to
normal activities or work 3e5 days earlier.
Primary failure of the ablated vein was a surrogate outcome of
clinical recurrence.39 Other causes may play a role on clinical
recurrence including below knee GSV reﬂux,40 reﬂux in
tributaries,41 neovascularisation,42 saphenopopliteal reﬂux,40 non-
axial branches23 and perforator insufﬁciency. Recurrence at a new
Table 3
Comparisons of postoperative complications between endovenous and surgical techniques.
Outcomes Comparison arms No. of studies No. of patients Heterogeneity Egger test Pooled RR (95%CI)
Q P I2(%) Βeta P
Wound infection EVLA vs Surgery 8 1347 2.07 0.956 0 0.71 0.232 0.3 (0.1, 0.8)
RFA vs Surgery 5 671 1.34 0.855 0 0.88 0.764 0.3 (0.1, 1.4)
Paresthesia EVLA vs Surgery 9 1387 7.83 0.450 0 0.60 0.274 0.8 (0.6, 1.1)
RFA vs Surgery 7 759 8.71 0.190 31.2 0.33 0.836 1.0 (0.5, 1.7)
Superﬁcial thrombophlebitis EVLA vs Surgery 6 1121 4.81 0.440 0 2.94 0.006 1.0 (0.5, 1.8)
RFA vs Surgery 6 699 5.45 0.364 8.2 0.41 0.718 2.3 (1.1, 5.0)
Haematoma EVLA vs Surgery 4 708 3.3 0.344 9.9 1.37 0.241 0.5 (0.3, 0.8)
RFA vs Surgery 5 437 11.17 0.025 64.2 1.56 0.163 0.4 (0.1, 0.8)
Ecchymosis EVLA vs Surgery 6 876 18.35 0.003 72.8 0.70 0.516 0.7 (0.3, 1.6)
CI, conﬁdence interval; RR, relative risk (Incidence Gr.1/Incidence Gr.2).
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incidence of reﬂux in tributaries and neovascularisation might
differ between the procedures with and without sapheno-femoral
ligation (i.e., more reﬂux in tributaries in the procedures without
sapheno-femoral ligation, and more neovascularisation after
sapheno-femoral ligation22,43,44) which may inﬂuence long-term
effectiveness between endovenous techniques and surgery in
addition to primary failure.
Pooling primary failure, reﬂux in tributaries and neo-
vascularisation together as composite outcomes of clinical recur-
rence resulted in dilution of the RR of EVLA and RFA versus surgery
to 1.1 (95% CI:0.6, 2.2; I2 ¼ 63.4%) and 1.1 (95% CI:0.6, 1.8;
I2 ¼ 20.7%), respectively (see Supplementary Fig. 10). Subgroup
analysis by follow-up and a sensitivity analysis excluding the cry-
ostripping study25 and EVLA with high ligation24,28 did not change
effects on efﬁcacy. These results and similarity of clinical recur-
rences demonstrated similarity of effectiveness of RFA and EVLA to
surgery. Although UGFS seems to be inferior to surgery, it is still
applied in clinical practise because of its lower cost, safety and
repeatability.4
For postoperative complications, RFA and EVLA had signiﬁcantly
lower wound infection and haematoma, but similar paresthesia
and ecchymosis compared to surgery. By contrast, RFA had signif-
icantly more superﬁcial thrombophlebitis than surgery. However,
these complications might be confounded by TA. Although
subgroup analyses by similar of TA in both interventions showed
similar results to overall poolings, these were based on small
numbers of studies. A sensitivity analysis excluding the study did
not perform concomitant phlebectomy26 left complication rates
unchanged. Deep venous thrombosis was not pooled because it was
rare and most studies reported no event.Table 4
Comparisons of postoperative pain, return to normal activities or work and quality of lif
Comparison arms Outcomes No. of studies Total number of pati
EVLA vs Surgery First reported pain 6 1010
Maximum pain 6 1010
NA or work 7 1227
NA 6 1132
AVVSS 6 1122
RFA vs Surgery First reported pain 4 438
Maximum pain 4 438
NA or work 6 727
NA 5 699
RFA vs EVLA First reported pain 4 542
Maximum pain 4 542
AVVSS, Aberdeen varicose vein severity scores; CI, conﬁdence interval; MD, weight mea
work, return to work.Our review suggested that EVLA and RFA had signiﬁcantly lower
pain scores than surgery with MD of 0.6 and 1.7, respectively.
These reached clinical signiﬁcance (at least 0.9) for RFA but not for
EVLA.45,46 Return to work was signiﬁcantly sooner with RFA than
with surgery but not for EVLA. This might result from different
ablativemechanismswhich can cause veinwall perforation in EVLA
(810 and 980 nm with bare tip),47 but not for RFA.48 This concern
has led to evolution of a new 1470-nm EVLA with a radial ﬁbre
which claimed to cause less pain with similar short term efﬁcacy.49
QOL in EVLA and surgery groups were not signiﬁcantly different.
Although all included studies used the same scale (i.e., AVVSS),
pooling was moderate heterogeneity (I2 ¼ 60.1%). None of the
sources (e.g., mean age, disease severity and follow-up time) could
explain heterogeneity.
Although the primary failures between EVLA and RFA versus
surgery were similar to previous meta-analyses,1,3,5,6 our evidence
was based on pooling of solely RCTs. Our results were also similar to
the most recent systematic review by the Cochrane50 while
preparing this article. However, more studies were pooled,
including three large RCTs11,23,38 and one study with long-term
follow-up.22 Consequently, our estimations of treatment effects
were more precise. For instance, we included seven studies in
pooling primary failure between EVLA versus surgery compared to
four for the Cochrane. The corresponding pooled RRs were 1.5 (95%
CI:0.7, 3.0) versus 3.30 (95% CI:0.8, 12.74). In addition, more
objective pooling of treatments effects on complications, pain,
return to normal activities and QOL were discussed in our review.
Furthermore, we assessed effects of RFA versus EVLA and UGFS. Our
results about the beneﬁt of less pain and return to normal activities
in EVLA and surgery were also consistent with, and more precise
than the results from a recent large RCT.38e between various endovenous and surgical techniques.
ents Heterogeneity Egger test WMD (95%CI)
Q P I2(%) Beta P
7.33 0.198 31.7 1.90 0.599 0.6 (1.1, 0.2)
7.59 0.180 34.1 1.84 0.610 0.6 (1.0, 0.1)
164.3 0.000 96.4 3.87 0.342 2.7 (6.0, 0.6)
159.1 0.000 96.9 6.17 0.208 3.5 (7.1, 0.0)
12.3 0.031 59.2 0.21 0.862 0.2 (0.9, 0.6)
0.59 0.899 0 1.85 0.341 1.6 (2.1, 1.1)
0.98 0.805 0 3.43 0.124 1.6 (2.0, 1.1)
38.23 0.000 86.9 1.71 0.516 4.9 (7.1, 2.7)
30.91 0.000 87.1 0.74 0.825 4.2 (6.5, 2.0)
11.65 0.009 74.3 3.36 0.512 0.8 (1.5, 0.1)
0.73 0.867 0 1.29 0.252 1.2 (1.6, 0.9)
n difference (mean of group 1 e mean of group 2); NA, return to normal activities;
B. Siribumrungwong et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 214e223222The strength of our study was included only in RCTs, the most
powerful design for therapeutic study. We considered all relevant
outcomes in all techniques currently used nowadays. Treatment
effects were mild to moderate heterogeneities with no evidence of
publication bias. Therefore, our results should help physicians
decide on the most appropriate interventions for their individual
patients. However, we had limitations. Some included studies were
correlated data, that is, different interventions were applied to the
same subjects. The units of analysis for these studies were number
of limbs, but pooling based on summary data did not allow
adjustment for this correlation. Duration of follow-up varied across
studies with a median of 12 months (range 0.2e60 months). Using
summary data did not allow us to explore short, intermediate and
long-term primary failures and other clinical outcomes of these
interventions. Only few studies22,31 with long-term follow-up (36
months or longer) were available. The clinical recurrences of
endovenous techniques seemed to be lower but not signiﬁcant than
surgery based on four studies. More studies with long-term follow-
up are necessary to update. Only one study23 reported cause of
clinical recurrence and thus we could not explore whether truncal
ablation or other causes play a role of clinical recurrence. Some
clinical outcomes (i.e., clinical recurrence, pain score and QOL) were
subjective and 56.5% of included studies were poor methodological
qualities from which they did not perform blind assessments. An
ascertainment bias of outcome measures might be present. Not all
included studies had applied ITT analysis for dealing with data; bias
from protocol violation (e.g., exclude cannulation failure, incom-
plete outcome or protocol violation) might be present.
Summary
In summary, UGFS seems inferior to surgery. Primary failure and
recurrence rates with EVLA and RFA were not different compared
with surgery, but had a lower rate of complications such as wound
infection and haematoma, less pain and shorter return to work.
Within the endovenous techniques, RFA seems to be slightly better
tolerated than EVLA except that it shows a signiﬁcantly higher rate
of superﬁcial thrombophlebitis.
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